0001209191-22-002168.txt : 20220106
0001209191-22-002168.hdr.sgml : 20220106
20220106161258
ACCESSION NUMBER: 0001209191-22-002168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220104
FILED AS OF DATE: 20220106
DATE AS OF CHANGE: 20220106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN LUKE
CENTRAL INDEX KEY: 0001134657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514957
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Foley Todd
CENTRAL INDEX KEY: 0001473930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514956
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014, L.P.
CENTRAL INDEX KEY: 0001609492
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514958
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 (B), L.P.
CENTRAL INDEX KEY: 0001609493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514955
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02124
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Asset Management Investors BV2014 LLC
CENTRAL INDEX KEY: 0001609495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514954
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BIOVENTURES 2018 (B), L.P.
CENTRAL INDEX KEY: 0001729504
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514951
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER NAME:
FORMER CONFORMED NAME: MPM BIOVENTURES 2018 (B) LP
DATE OF NAME CHANGE: 20180126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
CENTRAL INDEX KEY: 0001734817
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514950
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 LLC
CENTRAL INDEX KEY: 0001765021
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514953
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 GP LLC
CENTRAL INDEX KEY: 0001765091
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22514952
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-04
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001609492
MPM BioVentures 2014, L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001134657
EVNIN LUKE
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001473930
Foley Todd
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001609493
MPM BioVentures 2014 (B), L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001609495
MPM Asset Management Investors BV2014 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001765021
MPM BioVentures 2014 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001765091
MPM BioVentures 2014 GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001729504
MPM BIOVENTURES 2018 (B), L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001734817
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2022-01-04
4
S
0
94745
42.05
D
2790725
I
See Footnote
Common Stock
2022-01-04
4
S
0
19366
43.20
D
2771359
I
See Footnote
Common Stock
2022-01-04
4
S
0
6768
45.32
D
2764591
I
See Footnote
Common Stock
2022-01-04
4
S
0
7671
46.47
D
2756920
I
See Footnote
Common Stock
2022-01-05
4
S
0
18135
42.03
D
2738785
I
See Footnote
The shares were sold as follows: 56,414 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,959 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 35,653 by MPM BioVentures 2018, L.P. ("BV 2018") and 719 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,575,558 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 54,213 by AM BV2014, 995,065 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 19,634 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 11,534 by BV 2014, 390 by AM BV2014, 7,300 by BV 2018 and 142 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,564,024 by BV 2014, 97,289 by BV 2014(B), 53,823 by AM BV2014, 987,765 by BV 2018, 48,966 by BV 2018(B) and 19,492 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 4,050 by BV 2014, 133 by AM BV2014, 2,544 by BV 2018 and 41 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,559,974 by BV 2014, 97,289 by BV 2014(B), 53,690 by AM BV2014, 985,221 by BV 2018, 48,966 by BV 2018(B) and 19,451 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 4,590 by BV 2014, 154 by AM BV2014, 2,874 by BV 2018 and 53 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $46.965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,555,384 by BV 2014, 97,289 by BV 2014(B), 53,536 by AM BV2014, 982,347 by BV 2018, 48,966 by BV 2018(B) and 19,398 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 10,804 by BV 2014, 372 by AM BV2014, 6,824 by BV 2018 and 135 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,544,580 by BV 2014, 97,289 by BV 2014(B), 53,164 by AM BV2014, 975,523 by BV 2018, 48,966 by BV 2018(B) and 19,263 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
2022-01-06
/s/ Luke Evnin
2022-01-06
/s/ Todd Foley
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.
2022-01-06
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC
2022-01-06